Our partners
One of the things that makes AVEO stand out in our industry is the ability to collaborate with others who share our vision. By seeking out strong pharmaceutical and biotechnology partners, we are able to work together efficiently to bring cancer treatments to those who need them.
Who we work with
AVEO has the license to develop, manufacture, and commercialize tivozanib in all areas of the world except for Asia and the Middle East. The agreement also allows for clinical data information sharing.
AVEO licensing agreement grants Recordati the EU rights to tivozanib, in addition to other territories outside of North America. Recordati may use study data in return for research and development funding to AVEO.
Clinical trial agreement in which BMS supplies nivolumab for use with tivozanib in the TiNivo-2 study in patients with renal cell carcinoma.
Partnering with AVEO in a clinical supply agreement to evaluate durvalumab in combination with tivozanib in hepatocellular carcinoma.
Collaboration with AVEO to develop and study a first-in-class antibody radio-conjugate to create a novel targeted radiotherapy.
Alliance for Clinical Trials in Oncology Foundation
Research grant agreement to evaluate safety and efficacy of tivozanib in combination with pembrolizumab in a Phase 3 clinical trial for adjuvant treatment of renal cell carcinoma.
MD Anderson University of Texas
Investigator-initiated trial research agreement to evaluate safety and efficacy of tivozanib in combination with nivolumab in advanced non-clear cell renal cell carcinoma in a Phase 2 study.
National Cancer Institute’s Surgical Oncology Program
Cooperative research and development agreement to evaluate safety and efficacy of tivozanib in cholangiocarcinoma in a Phase 1-2 clinical trial.
University of Florida
Investigator-sponsored trial agreement to evaluate safety and efficacy of tivozanib in combination with atezolizumab in immunologically cold tumors in a Phase 1b/2 clinical trial.